PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16803227

Search for Z' --> e+ e- using dielectron mass and angular distribution.

A Abulencia·D Acosta·J Adelman·T Affolder·T Akimoto·M G Albrow·D Ambrose·S Amerio·D Amidei·A Anastassov·K Anikeev·A Annovi·J Antos·M Aoki·G Apollinari·J-F Arguin·T Arisawa·A Artikov·W Ashmanskas·A Attal·F Azfar·P Azzi-Bacchetta·P Azzurri·N Bacchetta·H Bachacou·W Badgett·A Barbaro-Galtieri·V E Barnes·B A Barnett·S Baroiant·V Bartsch·G Bauer·F Bedeschi·S Behari·S Belforte·G Bellettini·J Bellinger·A Belloni·E Ben Haim·D Benjamin·A Beretvas·J Beringer·T Berry·A Bhatti·M Binkley·D Bisello·R E Blair·C Blocker·B Blumenfeld·A Bocci·A Bodek·V Boisvert·G Bolla·A Bolshov·D Bortoletto·J Boudreau·A Boveia·B Brau·C Bromberg·E Brubaker·J Budagov·H S Budd·S Budd·K Burkett·G Busetto·P Bussey·K L Byrum·S Cabrera·M Campanelli·M Campbell·F Canelli·A Canepa·D Carlsmith·R Carosi·S Carron·M Casarsa·A Castro·P Catastini·D Cauz·M Cavalli-Sforza·A Cerri·L Cerrito·S H Chang·J Chapman·Y C Chen·M Chertok·G Chiarelli·G Chlachidze·F Chlebana·I Cho·K Cho·D Chokheli·J P Chou·P H Chu·S H Chuang·K Chung·W H Chung·Y S Chung·M Ciljak·C I Ciobanu
View original source ↗Export metadata ↓

Abstract

We search for Z' bosons in dielectron events produced in pp collisions at square root of s = 1.96 TeV, using 0.45 fb(-1) of data accumulated with the Collider Detector at Fermilab II detector at the Fermilab Tevatron. To identify the Z' --> e+ e- signal, both the dielectron invariant mass distribution and the angular distribution of the electron pair are used. No evidence of a signal is found, and 95% confidence level lower limits are set on the Z' mass for several models. Limits are also placed on the mass and gauge coupling of a generic Z', as well as on the contact-interaction mass scales for different helicity structure scenarios.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Abulencia, D Acosta, J Adelman, T Affolder, T Akimoto, M G Albrow, D Ambrose, S Amerio, D Amidei, A Anastassov, K Anikeev, A Annovi, J Antos, M Aoki, G Apollinari, J-F Arguin, T Arisawa, A Artikov, W Ashmanskas, A Attal, F Azfar, P Azzi-Bacchetta, P Azzurri, N Bacchetta, H Bachacou, W Badgett, A Barbaro-Galtieri, V E Barnes, B A Barnett, S Baroiant, V Bartsch, G Bauer, F Bedeschi, S Behari, S Belforte, G Bellettini, J Bellinger, A Belloni, E Ben Haim, D Benjamin, A Beretvas, J Beringer, T Berry, A Bhatti, M Binkley, D Bisello, R E Blair, C Blocker, B Blumenfeld, A Bocci, A Bodek, V Boisvert, G Bolla, A Bolshov, D Bortoletto, J Boudreau, A Boveia, B Brau, C Bromberg, E Brubaker, J Budagov, H S Budd, S Budd, K Burkett, G Busetto, P Bussey, K L Byrum, S Cabrera, M Campanelli, M Campbell, F Canelli, A Canepa, D Carlsmith, R Carosi, S Carron, M Casarsa, A Castro, P Catastini, D Cauz, M Cavalli-Sforza, A Cerri, L Cerrito, S H Chang, J Chapman, Y C Chen, M Chertok, G Chiarelli, G Chlachidze, F Chlebana, I Cho, K Cho, D Chokheli, J P Chou, P H Chu, S H Chuang, K Chung, W H Chung, Y S Chung, M Ciljak, C I Ciobanu. 2006-05-30. Search for Z' --> e+ e- using dielectron mass and angular distribution.. https://doi.org/10.1103/physrevlett.96.211801

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗